Rampart Bioscience
Minh-Ha T. Do currently serves as Vice President of Research at Rampart Bioscience, where responsibilities include overseeing non-clinical in vivo pharmacology and toxicology for cell and gene therapy programs. Previously, at Lumos Pharma, Minh-Ha held the position of Director of Pre-Clinical Innovation, managing various non-clinical development aspects for rare disease programs and authoring regulatory documents. Minh-Ha's earlier tenure at aTyr Pharma involved significant roles, including Associate Director and Program Scientific Lead, focusing on advancing biotechnology therapeutics and engaging with regulatory agencies. Minh-Ha holds a Ph.D. in Biomedical Sciences from UC San Diego and a Bachelor's Degree in Molecular, Cellular and Developmental Biology from UCLA.
This person is not in any teams
This person is not in any offices
Rampart Bioscience
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies. Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.